KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Intangibles (2016 - 2019)

Arbutus Biopharma's Intangibles history spans 5 years, with the latest figure at $43.8 million for Q2 2019.

  • For Q2 2019, Intangibles fell 25.25% year-over-year to $43.8 million; the TTM value through Jun 2019 reached $43.8 million, down 25.25%, while the annual FY2017 figure was $58.6 million, 41.03% down from the prior year.
  • Intangibles for Q2 2019 was $43.8 million at Arbutus Biopharma, roughly flat from $43.8 million in the prior quarter.
  • Across five years, Intangibles topped out at $390.0 million in Q2 2015 and bottomed at $43.8 million in Q3 2018.
  • The 5-year median for Intangibles is $99.4 million (2016), against an average of $171.4 million.
  • The largest YoY upside for Intangibles was 9.5% in 2016 against a maximum downside of 71.8% in 2016.
  • A 5-year view of Intangibles shows it stood at $352.6 million in 2015, then tumbled by 71.8% to $99.4 million in 2016, then crashed by 41.03% to $58.6 million in 2017, then fell by 25.25% to $43.8 million in 2018, then changed by 0.0% to $43.8 million in 2019.
  • Per Business Quant, the three most recent readings for ABUS's Intangibles are $43.8 million (Q2 2019), $43.8 million (Q1 2019), and $43.8 million (Q3 2018).